KDM1A and acute myeloid leukemia: Several LSD1 inhibitors such as Bomedemstat, Iadademstat, etc. are in clinical trials for the treatment of AML, MPN, SCLC, etc. Vafidemstat a dual LSD1 and MAO-B targeting inhibitor is in clinical trial for the treatment of CNS disorders [13–17].